Two University of Houston (UH) professors are developing a computerized modeling system to cut the development time of new antibiotics.
Vincent Tam, associate professor of clinical sciences, and Michael Nikolaou, professor of chemical and biomolecular engineering, are focusing on dosing regimens to reveal which ones are most likely to be effective in combating infection and which are not worth pursuing.
It is hoped that pharmaceutical companies can then focus their tests on the most promising regimens.
“With microbial resistance to drugs increasing, there is a need to develop new antimicrobial agents rapidly. Our work proposes a new computational method that will provide quantitative insight to the interaction between certain antibiotics and pathogens. Through pharmacodynamic modeling, which studies the effects of drugs on organisms, our aim is to both help develop new antibiotics and optimize existing medications to curb the prevalence of drug-resistant bacteria,” Tam said.
The traditional approach to drug development involves a great deal of trial-and-error testing, such as empirically selecting a handful of dosing regimens for clinical investigations among hundreds of possibilities – only time will tell its effectiveness.
Tam and Nikolaou, however, are employing computer modeling and simulation to project how bacteria would respond to different exposures of a drug, focusing on how much medicine a patient should take, how often it should be taken and for how many days.
Subsequent investigations in clinical studies can then target those dosing methods that have the highest probabilities of success.
Tam, an expert on experimental therapeutics, and Nikolaou, with a background in computer-aided systems engineering, forged their collaboration through a seed grant from UH before they attracted external funding.
Their modeling approach relies on fundamental laws of nature, which are exploited to generate future projections from scant experimental inputs through computer simulation. This has been demonstrated to be better than simple human eyeballing.
“Our approach gives us the ability to take extra variables into consideration in an attempt to develop a more robust computational tool that covers a wider spectrum of relevant scenarios in new drug development. Some pharmaceutical companies are following our developments closely, and we are in the process of refining a model prototype in the form of a computer program to ultimately be used in a clinical setting,” Nikolaou said.
The findings appear in the Public Library of Science”s PLoS Computational Biology. (ANI)